Forward March: Push Continues for Immunotherapy in Prostate Cancer
September 20, 2016 – Aimee Swartz
Creating a Diversion: Life After Cystectomy for Bladder Cancer
September 22, 2016 – Leah K. Lawrence
A Sign of the Times: The Changing Treatment Landscape for Advanced Kidney Cancer
September 23, 2016 – Marijke Vroomen Durning, RN
Hard to Hear: Cisplatin Can Cause Hearing Loss for Men With Testicular Cancer
September 23, 2016 – Karen Bruno
From Rags to Riches: Bladder Cancer Research Rife With New Approaches
September 27, 2016 – Arlene Weintraub
On the Side: An Overview of Prostate Cancer Treatment Side Effects
September 27, 2016 – Beth Fand Incollingo
Honing in on Bladder Cancer: Key Facts
September 28, 2016 – Arlene Weintraub and CURE staff
Cystectomy to Treat Bladder Cancer: It's Complicated
September 28, 2016 – Leah K. Lawrence and CURE staff
Prioritizing Clinical Trials Led to New Therapies for Kidney Cancer
September 23, 2016 – Debu Tripathy, M.D.
Currently Viewing
Another Reason for Excitement About Cancer Immunotherapy
September 23, 2016 – Mike Hennessy, Sr.
Prostate Cancer Screening: Where Do We Stand?
September 29, 2016
Q & A With Olympian Scott Hamilton: Turning Cancer Upside Down
September 29, 2016 – Laura Panjwani

Another Reason for Excitement About Cancer Immunotherapy

In discussions of cancer these days, there may be no word mentioned more often than “immunotherapy,” and bladder cancer provides us with an excellent example of why this strategy is so important, writes our chairman and CEO, Mike Hennessy, Sr.
BY Mike Hennessy, Sr.
PUBLISHED September 23, 2016
IN DISCUSSIONS OF CANCER these days, there may be no word mentioned more often than “immunotherapy,” and bladder cancer provides us with an excellent example of why this strategy is so important.

When the immunotherapy Tecentriq (atezolizumab) was approved for the treatment of advanced bladder cancer in May 2016, it became the first new therapy for patients in that population in 30 years.

Our special issue on genitourinary cancers brings you an article that shares details about this exciting breakthrough. We explain the mechanism of action of Tecentriq, an immune checkpoint inhibitor that frees up the body’s immune system to fight cancer, and we identify a number of similar drugs — as well as targeted agents — that are being tested in clinical trials for the treatment of this disease.

This issue also brings news of immunotherapy successes in other GU cancer types. The immune checkpoint inhibitor Keytruda (pembrolizumab) was recently approved to treat advanced renal cell carcinoma, and, in a clinical trial, the same drug is showing promising results in men with prostate cancer.

In this issue, we offer some practical thoughts on life after cystectomy for bladder cancer — particularly the sometimes difficult adjustment to using a neobladder — and facts patients should know about the association between treatment with cisplatin chemotherapy and hearing loss.

Finally, Olympic gold medal-winning figure skater Scott Hamilton, in an exclusive interview with CURE, shares recollections about his mother’s cancer journey, his own fight against the disease and his latest efforts to help support patients.

We hope you’ll find a healthy balance of education, hope and inspiration in this special issue on genitourinary cancers.

As always, thank you for reading.

MIKE HENNESSY, SR
Chairman and CEO
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In